Nano-X Imaging heads into its third-quarter report with a credibility problem that a single quarter of revenue cannot fully solve. Management has spent the past year pushing back the moment when its ARC imaging systems would start producing meaningful revenue. The target moved from the second half of 2026, to the third quarter, and most recently to the next few months. Meanwhile, the cash balance has fallen from $60 million at the end of 2025 to $31.4 million by mid-year. When the company reports before the open on November 25, the question is less about whether it hits a number. It is whether the business can show traction quickly enough to matter for its funding position.
The revenue setup is unusually clear because management has already told the market what to expect. Nanox guided third-quarter revenue to $4.3 million to $4.4 million, well below the roughly $5.45 million consensus. The Street is sitting above the company's own outlook, so a headline miss against consensus would be no surprise. The more useful comparison is internal. The guided range implies roughly 28% growth over the $3.4 million reported a year ago, but it is essentially flat with the second quarter's $4.2 million. That sequential stall matters. Second-quarter growth was helped by about $0.9 million from consolidating Nanox Health IT rather than by core ARC sales. Flat revenue in the third quarter would therefore suggest the ARC ramp has not yet arrived. Published per-share estimates are not meaningful at this point. The year-ago loss of $0.65 per share and the prior quarter's $0.79 loss are better reference points for whether cost actions are taking hold.
The operational evidence that would validate last quarter's narrative falls into three areas. First, management highlighted the new CMS reimbursement code G0680 for its AI cardiac analysis, effective in April. It also pointed to the first Nanox imaging network site in Philadelphia, which is already generating paid claims of $200 to $700 each. Any sign of additional network sites, rising claim volume, or early billing under the new code would show that the higher-reimbursement model can scale beyond a single location. Second, the company now has 10 U.S. distribution partners plus new agreements in Costa Rica and the UK. Investors should look for those relationships to translate into installed and revenue-generating ARC units, not just signed contracts. Third, the non-GAAP gross loss margin improved to negative 13% from negative 29% a year earlier. Further progress toward breakeven at the gross line would suggest pricing and service economics are maturing.
What would challenge the story is equally clear. Management repeatedly blamed permitting, shielding, construction, and workflow integration for delayed revenue recognition. Another round of those same explanations, without concrete deployment counts, would deepen skepticism. Cash is the bigger swing factor. Quarterly burn has run near $14 million, and the company has raised $8.5 million since the second quarter through an at-the-market program and a registered direct offering. Simple arithmetic points to a balance somewhere in the mid-$20 millions, with the going-concern doubt still hanging over the company. The roughly $2 million in annualized savings from cuts in Korea and Israel does not take effect until 2027, so any faster reduction in burn would be welcome.
The market has already rendered a harsh verdict. Shares have dropped about 62% since the last report, against a 4% decline in the S&P 500. At $0.29, the stock trades far below its 200-day average of $1.44 and near the bottom of its post-earnings range of $0.21 to $0.81. Sentiment has nonetheless improved markedly from deeply pessimistic levels a quarter ago. That suggests some investors see the guided shortfall as already priced in and are looking for signs of stabilization.
Ultimately, this report will be judged on runway and proof of demand together. If Nanox can show ARC units moving into paid use, imaging network claims building, and a credible path to slower cash burn, last quarter's operational green shoots will start to look like a business. If revenue lands flat and burn persists, the conversation will stay centered on dilution and survival rather than growth.